Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. (February 2016)

• Record Type: Journal Article
• Authors: Veccia, Antonello; Caffo, Orazio; De Giorgi, Ugo; Di Lorenzo, Giuseppe; Ortega, Cinzia; Scognamiglio, Florinda; Aieta, Michele; Facchini, Gaetano; Mansueto, Giovanni; Mattioli, Rodolfo; Procopio, Giuseppe; Zagonel, Vittorina; D'Angelo, Alessandro; Spizzo, Gilbert; Bortolus, Roberto; Donini, Maddalena; Lo Re, Giovanni; Massari, Francesco; Vicario, Giovanni; Zucali, Paolo A; Alesini, Daniele; Bonetti, Andrea; Mucciarini, Claudia; Nicodemo, Maurizio; Berruti, Alfredo; Fratino, Lucia; Lodde, Michele; Messina, Caterina; Perin, Alessandra; Santini, Daniele; Sava, Teodoro; Tucci, Marcello; Basso, Umberto; Maines, Francesca; Burgio, Luca S; Galligioni, Enzo;
• Is Part Of: Future oncology. Volume 12:Number 4(2016)
• Page Start: 493
• Page End: 502
• Publication Date: 2016-02
• Subjects: castration-resistant prostate cancer -- docetaxel -- elderly -- geriatric assessment; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.15.302
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: To assess clinical outcomes in octogenarians treated with docetaxel (DOC) for metastatic castration-resistant prostate cancer.Patients & methods: The multicenter retrospective study was based on a review of the pre- and post-DOC clinical history, DOC treatment and outcomes.Results: We reviewed the records of 123 patients (median age: 82 years) who received DOC every 3 weeks or weekly, without significant grade 3–4 toxicities. Median progression-free survival was 7 months; median overall survival from the start of DOC was 20 months, but post-progression treatments significantly prolonged overall survival.Conclusion: The findings of this study suggest that toxicity is acceptable, survival is independent of patient's age and survival can be significantly prolonged by the use of new agents.